UVC PureLight 360​ Proven To Kill The Spread Of COVID-19 Coronavirus

UVC PureLight 360​, a new UVC induction light disinfection and sanitization technology, has passed testing that shows the technology kills the indoor spread of numerous pathogens, including COVID-19 Coronavirus.

UVC PureLight 360 Test results from a leading independent international laboratory confirm that the patent-pending 320W UVC Induction/LED prototype from Miami-based UVC PureLight 360 LLC inactivates more than 99.9% of COVID-19 in a 16′ X 16′ room in as little as 3.5 minutes.

COVID-19 has caused more than 1.2 million deaths worldwide in 2020, and the resurgence of the virus in the U.S. has led to more than 10 million current infections.

“UVC light is a proven method to sanitize indoor spaces from many known pathogens, and it’s a critical health advancement to know that our new technology kills the spread of this deadly virus,” said Dr. Minghsun Liu, microbiologist, infectious disease specialist, and UVC PureLight 360TM advisory board member.

The technology also kills germs and bacteria that cause common colds and flu, SARS, MERS, H1N1 and other health threats.

UVC PureLight 360​TM was developed to create safe, clean indoor spaces in a wide variety of locations such as medical facilities, hotels, offices, schools, retail, fitness centers, restaurants and more.

“When launching UVC PureLight 360, we wanted to ensure our device was an effective, tested and proven solution for all these settings,” said Alan Mandel, CEO and co-founder of UVC PureLight 360 LLC. “These verified test results prove our mission to help guests, patients and staff have peace of mind. This is a big step in overcoming the pandemic, as well as the economic hardship it has caused.”

In addition to quickly killing virulent pathogens, the UVC light leaves behind no odors or damaging residues. Currently, most businesses and facilities must spray or wipe down surfaces with harsh chemicals and other antibacterial products to remediate COVID-19.

UVC PureLight 360​TM features a hybrid UVC and LED bulb tower atop a maneuverable cart for easy room-to-room transport. The 320W output is precisely calculated to be effective against a wide range of bacteria and viruses.

The production version of the device is expected to launch in January when health officials fear COVID-19 infections will be surging. While the device is in final development, the company is aligning with distributors across the globe.

“COVID-19 has been an unprecedented public health and economic crisis,” Mandel said. “We’re proud to deliver this solution to businesses, institutions, and the public.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version